X

Cookies

Continue We want you to get the most out of using this website, which is why we and our partners use cookies. By continuing to use this site, you are agreeing to receive these cookies. You can find out more about how we use cookies here.

Thursday, 30 October 2014

Subscriptions  |  evouchers  |  Jobs  |  Property  |  Motors  |  Travel  |  Dating  |  Family Notices

GlaxoSmithKline Ulverston site interested in Furness windfarm

ENERGY provider Infinergy has announced Glaxo Ulverston pharmaceutical site has expressed an interest in buying power from a proposed Furness windfarm.

Infinergy has revealed it is in discussions with GlaxoSmithKline’s Ulverston site which is looking at options to source green power for its Cumbrian manufacturing facility where it makes active pharmaceutical ingredients for antibiotics.

Furness Wind Farm is a partnership project between Infinergy and community cooperative Baywind, which is seeking planning permission to replace Baywind’s existing five Harlock Hill wind turbines with five new turbines.

Infinergy said that if the proposed Furness Wind Farm gets the go ahead, Infinergy would own three wind turbines and Baywind would own two. GSK Ulverston potentially could use all of the electricity from Infinergy’s three new turbines, which could have an installed capacity of up to 6.9 megawatts.

The annual power output of these turbines could reduce the GSK site’s carbon footprint by approximately 25 per cent.

A GSK spokesman said: “In line with the company’s global drive to be more sustainable, GSK Ulverston has a target of reducing the site’s carbon footprint by 30 per cent by the end of 2014 compared with 2011.

“The Furness Wind Farm presents GSK with an opportunity to achieve this ambition.

“Competitively priced energy will also help to improve the site’s overall operating costs, enhancing Ulverston’s ability to increase output of active ingredients for antibiotics to take advantage of a growing global market.”

 Last year, Glaxo announced Ulverston had been selected as the site for a new £350m biopharmaceutical facility. Construction is set to begin in 2014 and the new plant is expected to create hundreds of jobs.

A spokesman for Infingery said: “With GSK Ulverston being a potential buyer of a substantial quantity of green electricity from the Furness Wind Farm, local stakeholder interest in the development has been boosted massively. Along with the Baywind Co-operative, which has many local shareholders and which would own the other two of the total of five turbines, local connections to the project are very strong.”

A Baywind spokesperson added: “GSK’s interest in Furness Wind Farm is fantastic news and we wholeheartedly welcome their support for the proposal. The involvement of a major Ulverston employer further strengthens the local benefits of the scheme. Through Baywind, local residents will also be offered the opportunity to buy affordable shares in the project.”

Have your say

Great stuff, the more local the benefits of wind turbines the better it is.

Posted by Molly on 14 March 2013 at 16:26

As one of the original investors with Baywind, I am extremely encouraged by the news of GSK investing in the area and making use of the energy that will be produced by the new, more efficient turbines and reducing their footprint, whilst providing much needed employment.

Posted by Belinda Mead on 29 January 2013 at 18:21

View all 8 comments on this article

Make your comment

Your name

Your Email

Your Town/City

Your comment


SHARE THIS ARTICLE

North West Evening Mail What's on search










Powered by
nwemail.co.uk/jobs

Hot Jobs

Loading latest hot jobs...
Powered by Zoopla.co.uk






Featured companies

Searching for featured companies...
Search for:

Vote

Is higher prize money for sportsmen than sportswomen fair?

Yes

No

Show Result


Go green 36

The Barber's Shop

Choosing a primary school

Kendall Brothers Ltd


To save our contact details direct to your smartphone simply scan this QR code

North West Evening Mail

Evening Mail Going Out